Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 10/20 | 0.56 |
| ▸ | GRIK2 | Q13002 | 9/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | PAM | P19021 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17926240 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL2031555 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL2029180 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL2029185 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL2031553 | 1.00 | GRIK1 (0.56) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL24704496 | 0.83 | HTR2A (0.53) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL19143267 | 0.80 | HTR2A (0.61) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL7310968 | 0.80 | HTR2A (0.61) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL7310970 | 0.80 | HTR2A (0.61) | GRIK1GRIK2HTR2APAMCTSC | |
| SCHEMBL21987028 | 0.79 | GRIK1 (0.65) | GRIK1GRIK2HTR2APAMGRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM CORPORATION (JP) | 2025-06-05 | — | — | US | disclosed |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130266597-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343475-B2 | Small cationic antimicrobial peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20110236429-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-20110150917-A1 | Small Cationic Antimicrobial Peptides | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2061886-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | The University of British Columbia (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008151434-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008022444-A1 | SMALL CATIONIC ANTIMICROBIAL PEPTIDES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | GRIK1 3324/4885GRIK2 3445/4885HTR2A 4346/4885 |
| US-20250179119-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MLX, BMX, ADM2 | GRIK1 3658/4885GRIK2 3015/4885HTR2A 4685/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | GRIK1 3939/4885GRIK2 4289/4885HTR2A 4741/4885 |
| US-20250179120-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | MDN1, MLX, BMX | GRIK1 3563/4885GRIK2 2984/4885HTR2A 4795/4885 |
| US-20250084410-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | RNGTT, TRMT1, OSGEP | GRIK1 4051/4885GRIK2 4260/4885HTR2A 4122/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | GRIK1 1482/4885GRIK2 1569/4885HTR2A 2216/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | GRIK1 1177/4885GRIK2 1610/4885HTR2A 3639/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | GRIK1 2202/4885GRIK2 2363/4885HTR2A 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.